[1]陈荔,吴大广,朱光宇,等.经动脉化疗栓塞联合免疫和靶向药治疗Child-Pugh B级肝细胞癌研究[J].介入放射学杂志,2024,33(09):968-973.
　CHEN Li,WU Daguang,ZHU Guangyu,et al.Transarterial chemoembolization combined with immune checkpoint inhibitor and molecular targeted therapy for Child-Pugh grade B hepatocellular carcinoma[J].journal interventional radiology,2024,33(09):968-973.
点击复制

经动脉化疗栓塞联合免疫和靶向药治疗Child-Pugh B级肝细胞癌研究()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
33
期数:
2024年09
页码:
968-973
栏目:
肿瘤介入
出版日期:
2024-09-17

文章信息/Info

Title:
Transarterial chemoembolization combined with immune checkpoint inhibitor and molecular targeted therapy for Child-Pugh grade B hepatocellular carcinoma
作者:
陈荔; 吴大广; 朱光宇; 仲斌演; 郭金和
Author(s):
CHEN Li; WU Daguang; ZHU Guangyu; ZHONG Binyan; GUO Jinhe.
Department of Interventional & Vascular Surgery，Affiliated Zhongda Hospital，Southeast University，Nanjing，Jiangsu Province 210009，China
关键词:
【关键词】肝细胞癌; 经动脉化疗栓塞; Child-Pugh分级B级
文献标志码:
A
摘要:
【摘要】目的探讨经动脉化疗栓塞（TACE）联合免疫检查点抑制剂（ICI）和分子靶向治疗对Child-Pugh（CP）分级B级肝细胞癌（HCC）的疗效和安全性。 方法筛选2018年1月至2021年5月在东南大学附属中大医院等3中心接受TACE联合ICI和分子靶向治疗（联合治疗组）或TACE单独治疗（单独治疗组）的CP B级HCC患者。主要终点为总生存期（OS），次要结局包括无进展生存期（PFS）、客观缓解率（ORR）和安全性。 结果126例患者纳入研究，其中联合治疗组64例，单独治疗组62例。联合治疗组、单独治疗组中位OS比较差异无统计学意义［17.7个月（95%CI：11.9～29.9）比13.2个月（95%CI：7.8～19.9），P=0.160］，联合治疗组中CP评分7分患者获得了明显更好的OS［19.0个月（95%CI：13.6～NR）比13.2个月（95%CI：8.0～NR），P=0.024］。两组中位PFS、ORR比较差异均无统计学意义（P=0.720、 P=0.960）。联合治疗组、单独治疗组分别有9例（14.1%）、6例（9.7%）患者出现3级/4级不良事件。 结论TACE联合免疫和靶向治疗CP B级HCC患者并未显示出比TACE单独治疗更好的预后，而联合治疗组CP评分7分患者OS明显更好。

参考文献/References:

［1］Villanueva A. Hepatocellular Carcinoma［J］. N Engl J Med，2019，380：1450-1462.
［2］Forner A，Reig M，Bruix J. Hepatocellular carcinoma［J］. Lancet，2018，391：1301-1314.
［3］Llovet JM，Kelley RK，Villanueva A，et al. Hepatocellular carcinoma［J］. Nat Rev Dis Primers，2021，7：6.
［4］Reig M，Forner A，Rimola J，et al. BCLC strategy for prognosis prediction and treatment recommendation：the 2022 update［J］. J Hepatol，2022，76：681-693.
［5］Park JW，Chen M，Colombo M，et al. Global patterns of hepatocellular carcinoma management from diagnosis to death：the BRIDGE Study［J］. Liver Int，2015，35：2155-2166.
［6］Llovet JM，De Baere T，Kulik L，et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma［J］. Nat Rev Gastroenterol Hepatol，2021，18：293-313.
［7］Llovet JM，Real MI，Montana X，et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma：a randomised controlled trial［J］. Lancet，2002，359：1734-1739.
［8］Lo CM，Ngan H，Tso WK，et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma［J］. Hepatology，2002，35：1164-1171.
［9］Chang X，Lu X，Guo J，et al. Interventional therapy combined with immune checkpoint inhibitors：emerging opportunities for cancer treatment in the era of immunotherapy［J］. Cancer Treat Rev，2019，74：49-60.
［10］Pinato DJ，Murray SM，Forner A，et al. Trans arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma：implications for immunotherapy［J］. J Immunother Cancer，2021，9：e003311.
［11］Tischfield DJ，Gurevich A，Johnson O，et al. Transarterial embolization modulates the immune response within target and nontarget hepatocellular carcinomas in a rat model［J］. Radiology，2022，303：215-225.
［12］Montasser A，Beaufrère A，Cauchy F，et al. Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma［J］. Histopathology，2021，79：36-46.
［13］Ben Khaled N，Seidensticker M，Ricke J，et al. Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma：the DEMAND trial protocol［J］. Future Oncol，2022，18：1423-1435.
［14］Llovet JM，Vogel A，Madoff DC，et al. Randomized phase 3 LEAP-012 study：transarterial chemoembolization with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma not amenable to curative treatment［J］. Cardiovasc Intervent Radiol，2022，45：405-412.
［15］Yang JD，Hainaut P，Gores GJ，et al. A global view of hepatocellular carcinoma：trends，risk，prevention and management［J］. Nat Rev Gastroenterol Hepatol，2019，16：589-604.
［16］Finn RS，Qin S，Ikeda M，et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma［J］. N Engl J Med，2020，382：1894-1905.
［17］Ren Z，Xu J，Bai Y，et al. Sintilimab plus a bevacizumab biosimilar（IBI305）versus sorafenib in unresectable hepatocellular carcinoma（ORIENT-32）：a randomised，open-label，phase 2-3 study［J］. Lancet Oncol，2021，22：977-990.
［18］Xu J，Shen J，Gu S，et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma（RESCUE）：a nonrandomized，open-label，phase Ⅱ trial［J］. Clin Cancer Res，2021，27：1003-1011.
［19］Finn RS，Ikeda M，Zhu AX，et al. Phase Ⅰb study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma［J］. J Clin Oncol，2020，38：2960-2970.
［20］European Association for the Study of the Liver.EASL clinical practice guidelines：management of hepatocellular carcinoma［J］. J Hepatol，2018，69：182-236.
［21］Marrero JA，Kulik LM，Sirlin CB，et al. Diagnosis，staging，and management of hepatocellular carcinoma：2018 practice guidance by the American Association for the Study of Liver Diseases［J］. Hepatology，2018，68：723-750.
［22］中国医师协会介入医师分会.中国肝细胞癌经动脉化疗栓塞治疗（TACE）临床实践指南［J］.介入放射学杂志，2018，27：1117-1126.
［23］Zhou J，Sun H，Wang Z，et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma（2019 edition）［J］. Liver Cancer，2020，9：682-720.
［24］Lu J，Zhao M，Arai Y，et al. Clinical practice of transarterial chemoembolization for hepatocellular carcinoma：consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology（ISMIO）［J］. Hepatobiliary Surg Nutr，2021，10：661-671.
［25］Lencioni R，Llovet JM. Modified RECIST（mRECIST）assessment for hepatocellular carcinoma［J］. Semin Liver Dis，2010，30：52-60.
［26］Kudo M，Matilla A，Santoro A，et al. CheckMate 040 cohort 5：a phase Ⅰ/Ⅱ study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis［J］. J Hepatol，2021，75：600-609.
［27］Fessas P，Kaseb A，Wang Y，et al. Post-registration experience of nivolumab in advanced hepatocellular carcinoma：an international study［J］. J Immunother Cancer，2020，8：e001033.
［28］D′Alessio A，Fulgenzi CAM，Nishida N，et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis：a real-world study［J］. Hepatology，2022，76：1000-1012.
［29］Wang Q，Xia D，Bai W，et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma：a multicentre observational study［J］. J Hepatol，2019，70：893-903.
［30］Choi TW，Kim HC，Lee JH，et al. The safety and clinical outcomes of chemoembolization in Child-Pugh class C patients with hepatocellular carcinomas［J］. Korean J Radiol，2015，16：1283-1293.

相似文献/References:

[1]李晓光,金征宇,杨宁,等.经动脉灌注化疗或栓塞治疗恶性胰岛素瘤肝转移[J].介入放射学杂志,2008,(11):803.
　LI Xiaoguang,JIN Zhengyu,YANG Ning,et al.Transcatheter arterial chemoperfusion or chemoembolizaiton for treatment of liver metastasis from malignant insulinoma[J].journal interventional radiology,2008,(09):803.
[2]姚志敏,佟小强,宋莉,等.宫颈癌术前动脉化疗栓塞疗效[J].介入放射学杂志,2009,(03):189.
　YAO Zhimin,TONG Xiaoqiang,SONG Li,et al.Preoperative transarterial chemoembolization for cervical cancer：analysis of efficacy[J].journal interventional radiology,2009,(09):189.
[3]张琳,牟玮,王健,等.乙酸化学消融联合肝动脉化疗栓塞治疗肝脏恶性肿瘤[J].介入放射学杂志,2007,(12):831.
　ZHANG Lin,MU Wei,WANG Jian,et al.CT fluoroscopic guidance percutaneous acetic acid injection tumor ablation and TACE for the malignant liver tumor[J].journal interventional radiology,2007,(09):831.
[4]王有枝,李彦豪,梅雀林,等.原发性肝癌肝动脉化疗栓塞术后继发溶血性尿毒综合征3例并文献复习[J].介入放射学杂志,2016,(06):543.
　WANG You-zhi,LI Yan-hao,MEI Que-lin,et al.Secondary hemolytic uremic syndrome occurring after transcatheter arterial chemoembolization for primary hepatocellular carcinoma: report of 3 cases with literature review [J].journal interventional radiology,2016,(09):543.
[5]王惠文,刘瑞宝,李晓婧,等.载药微球-TACE治疗难治性妇科恶性肿瘤肝转移12例[J].介入放射学杂志,2021,30(06):568.
　WANG Huiwen,LIU Ruibao,LI Xiaojing,et al.Drug- eluting beads - TACE for the treatment of refractory liver metastases from synecological malignant tumors： preliminary results in 12 patients[J].journal interventional radiology,2021,30(09):568.
[6]蒋健强,李晓娟,李拥军,等.白蛋白-胆红素评分在预测TACE治疗巨块型肝细胞癌后肝功能衰竭中的应用[J].介入放射学杂志,2023,32(01):55.
　JIANG Jianqiang,LI Xiaojuan,LI Yongjun,et al.The application of albumin-bilirubin score in predicting liver failure after transarterial chemoembolization for massive hepatocellular carcinoma [J].journal interventional radiology,2023,32(09):55.
[7]刘　晟,周平盛,沈　强,等.超声引导下微波消融术治疗特殊部位与非特殊部位单发肝细胞癌的疗效对比[J].介入放射学杂志,2023,32(01):36.
　LIU Sheng,ZHOU Pingsheng,SHEN Qiang,et al.Ultrasound-guided microwave ablation for the treatment of single hepatocellular carcinoma located at specific area and at non-specific area: comparison of clinical efficacy[J].journal interventional radiology,2023,32(09):36.
[8]王　曦,冯　苏,李　红,等.免疫检查点抑制剂联合TACE在肝癌治疗中的研究进展[J].介入放射学杂志,2023,32(01):90.
　WANG Xi,FENG Su,LI Hong,et al.Research progress in immune checkpoint inhibitors combined with TACE for the treatment of hepatocellular carcinoma[J].journal interventional radiology,2023,32(09):90.
[9]吴迪,郑琳.载药微球栓塞治疗在肝癌全程管理中的临床应用进展[J].介入放射学杂志,2024,33(08):921.
　WU Di,ZHENG Lin..Application progress of drug-loaded microspheres embolization therapy in the clinical full-process management of hepatocellular carcinoma[J].journal interventional radiology,2024,33(09):921.
[10]石佳鹏,汤小星,顾祝新,等.TACE联合瑞戈非尼及PD-1二线序贯治疗中晚期肝细胞癌的临床研究[J].介入放射学杂志,2024,33(09):995.
　SHI Jiapeng,TANG Xiaoxing,GU Zhuxin,et al.TACE combined with regorafenib and PD-1 second-line sequential therapy for advanced hepatocellular carcinoma：a clinical study[J].journal interventional radiology,2024,33(09):995.

备注/Memo

备注/Memo:
（收稿日期：2023-11-06）
（本文编辑：谷珂）
更新日期/Last Update: 2024-09-15